Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

PURPOSE AND DESIGN: Mechanism(s) by which the multi-kinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal and pancreatic adenocarcinoma cells have been defined. RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic f...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Zhang, Guo, Park, Margaret A., Mitchell, Clint, Hamed, Hossein, Rahmani, Mohammed, Martin, Aditi Pandya, Curiel, David T., Yacoub, Adly, Graf, Martin, Lee, Ray, Roberts, John D., Fisher, Paul B., Grant, Steven, Dent, Paul
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2561272/
https://ncbi.nlm.nih.gov/pubmed/18765530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0469
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki